Latest On Pluristem Therapeutics Inc (PSTI):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2022-07-25 17:34 EST | News | Pluristem Therapeutics renames as Pluri | N/A |  |
| 2022-07-13 20:06 EST | News | Pluristem says Phase 3 trial for muscle injury therapy did not meet key goal | N/A | |
| 2022-03-24 21:33 EST | News | Pluristem PLX-R18 shows promise in blood cell recovery in cell transplant patients in trial | N/A | |
| 2022-01-10 07:36 EST | News | Pluristem jumps 31% on collaboration with Tnuva to develop cultured cell-based food products | N/A | |
| 2021-12-27 18:40 EST | News | Pluristem's Phase II PLX-PAD cells studies in COVID-19 fail to meet primary endpoint | N/A | |
| 2021-10-14 23:47 EST | News | Warning: PSTI is at high risk of performing badly | N/A | |
| 2021-10-06 15:23 EST | News | PSTI is at high risk of performing badly | N/A | |
| 2021-09-29 21:44 EST | News | Warning: PSTI has been downgraded to Very Bearish | N/A | |
| 2021-07-21 20:40 EST | News | Pluristem rises 7% following €20M funding from European Investment Bank | N/A | |
| 2021-07-21 20:02 EST | News | Pluristem brings Phase II COVID-19 ARDS studies to clinical readout; topline data expected in Q4 | N/A | |
| 2021-04-29 19:26 EST | News | Pluristem shares rise 13% on promising PLX-R18 results in hematology program | N/A | |
| 2021-02-17 08:14 EST | Analyst Rating | The Analyst Target Price has increased from $8.8 to $9. | Buy | |
| 2021-02-12 08:24 EST | Analyst Rating | The Analyst Target Price has increased from $8.6 to $8.8. | Buy | |
| 2021-02-10 08:17 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-02 12:27 EST | News | Pluristem Therapeutics launches $30M registered direct offering | N/A | |
| 2020-12-29 21:04 EST | News | Pluristem expands COVID-19 program in Mexico | N/A | |
| 2020-12-15 12:44 EST | Analyst Rating | The Analyst Target Price has decreased from $9.2 to $8.6. | Neutral | |
| 2020-12-14 08:33 EST | Analyst Rating | The Analyst Target Price has decreased from $9.6 to $9.2. | Neutral | |
| 2020-12-11 12:30 EST | Analyst Rating | The Analyst Target Price has decreased from $16.1 to $9.6. | Neutral | |
| 2020-12-09 23:20 EST | News | Pluristem plunges 42% as CLI trial unlikely to meet primary endpoint, study terminated | N/A | |
| 2020-12-08 10:36 EST | News | Pluristem - Moment Of Truth | N/A | |
| 2020-11-26 21:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-10 04:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 00:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 16:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-06 08:40 EST | Earnings Estimate | An EPS average of -$0.10 is estimated for the quarter ending on March 31, 2021. | Buy | |
| 2020-11-03 17:03 EST | Insider Trade | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER has directly acquired 25,000 shares and currently holds 4,057,589 shares. | Buy | |
| 2020-11-03 17:03 EST | Insider Trade | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER has directly acquired 25,000 shares and currently holds 4,032,589 shares. | Buy | |
| 2020-10-30 09:58 EST | Insider Trade | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER has directly acquired 20,000 shares and currently holds 4,007,589 shares. | Buy | |
| 2020-10-20 02:58 EST | News | Pluristem Therapeutics (PSTI) - Investor Presentation - Slideshow | N/A | |
| 2020-10-13 17:19 EST | News | Pluristem on go with cohort II of mid-stage chronic graft vs host disease study | N/A | |
| 2020-10-08 01:58 EST | News | Pluristem to conduct Phase II COVID-19 European trial in Israel | N/A | |
| 2020-10-03 05:54 EST | News | Pluristem Therapeutics up on insider buy | N/A | |
| 2020-10-01 16:29 EST | Insider Trade | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER has directly acquired 139,006 shares and currently holds 3,987,589 shares. | Buy | |
| 2020-10-01 16:29 EST | Insider Trade | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER has directly acquired 60,123 shares and currently holds 3,848,583 shares. | Buy | |
| 2020-09-29 16:49 EST | Insider Trade | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER has directly acquired 13,189 shares and currently holds 3,788,460 shares. | Buy | |
| 2020-09-26 13:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-25 16:17 EST | Insider Trade | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER has directly acquired 34,800 shares and currently holds 3,775,271 shares. | Buy | |
| 2020-09-24 16:42 EST | Insider Trade | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER has directly acquired 2,276 shares and currently holds 3,740,471 shares. | Buy | |
| 2020-09-24 16:42 EST | Insider Trade | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER has directly acquired 8,458 shares and currently holds 3,738,195 shares. | Buy | |
| 2020-09-17 05:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-15 23:14 EST | News | Pluristem to complete enrollment in Phase II COVID-19 study in Q1 2021 | N/A | |
| 2020-09-12 01:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-11 05:22 EST | Earnings Estimate | An EPS average of -$0.24 is estimated for the 2022 year. | Buy | |
| 2020-09-11 05:22 EST | Earnings Estimate | An EPS average of -$0.27 is estimated for the quarter ending on December 31, 2020. | Buy | |
| 2020-09-10 17:57 EST | Insider Trade | Moria Kwiat has directly acquired 20,000 shares and currently holds 57,357 shares. | Buy | |
| 2020-09-10 17:13 EST | Insider Trade | Zami Aberman has directly acquired 500,000 shares and currently holds 1,493,973 shares. | Buy | |
| 2020-09-10 17:13 EST | Insider Trade | YAKY YANAY has directly acquired 500,000 shares and currently holds 1,425,304 shares. | Buy | |
| 2020-09-10 17:13 EST | Insider Trade | Zami Aberman has directly acquired 500,000 shares and currently holds 993,973 shares. | Buy | |
| 2020-09-10 17:13 EST | Insider Trade | YAKY YANAY has directly acquired 500,000 shares and currently holds 925,304 shares. | Buy | |
About Pluristem Therapeutics Inc (PSTI):
Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermittent claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has collaboration agreements with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions; and BIH Center for Regenerative Therapy and Berlin Center for Advanced Therapies to expand its framework and research agreement, as well as conduct a joint project evaluating the therapeutic effects of the registrant's patented PLX cell product candidates for treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.
General
- Name Pluristem Therapeutics Inc
- Symbol PSTI
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 146
- Last Split Factor1:10
- Last Split Date2019-07-25
- Fiscal Year EndJune
- IPO Date2003-06-30
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.pluristem.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 6976.08
- Price/Book (Most Recent Quarter) 4.04
- Enterprise Value Revenue 6562.71
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.43
- Next Year EPS Estimate -$1.30
- Next Quarter EPS Estimate -$0.25
- Return on Assets -61%
- Return on Equity -129%
- Earnings Per Share -$2.86
- Revenue Per Share $0
- Gross Profit 23000
- Quarterly Earnings Growth -54%
View More
Highlights
- Market Capitalization 172.15 million
- EBITDA -33570000
- Analyst Target Price $9
- Book Value Per Share $1.59
View More
Share Statistics
- Shares Outstanding 31.53 million
- Shares Float 23.84 million
- % Held by Insiders 1994%
- % Held by Institutions 11.64%
- Shares Short 489811
- Shares Short Prior Month 558924
- Short Ratio 0.61
- Short % of Float 2%
- Short % of Shares Outstanding 2%
View More
Technicals
- Beta 2.54
- 52 Week High $13.29
- 52 Week Low $2.9
- 50 Day Moving Average 6.49
- 200 Day Moving Average 8.42
View More
Dividends
- Dividend Date 2019-07-25
- ExDividend Date N/A
- Dividend Yield 0%
View More
Pluristem Therapeutics Inc (PSTI) Dividend Calendar:
PSTI's last dividend payment was made to shareholders on July 25, 2019.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Pluristem Therapeutics Inc (PSTI) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-08 | $N/A | -$0.49 | -$0.33 | -48.48% |
| 2020-09-30 | 2020-11-05 | $N/A | -$0.33 | -$0.23 | -46.67% |
| 2020-06-30 | 2020-09-10 | $N/A | -$0.32 | -$0.36 | 11.11% |
| 2020-03-31 | 2020-05-11 | $N/A | -$0.42 | -$0.38 | -9.57% |
| 2019-12-31 | 2020-02-06 | $23000 | -$0.40 | -$0.54 | 25.93% |
| 2019-09-30 | 2019-11-07 | $N/A | -$0.46 | -$0.62 | 25.81% |
| 2019-06-30 | 2019-09-12 | $N/A | -$0.50 | -$0.67 | 25% |
| 2019-03-31 | 2019-05-06 | $N/A | -$0.90 | -$0.75 | -20% |
| 2018-12-31 | 2019-02-06 | $50000 | -$0.70 | -$0.87 | 19.23% |
| 2018-09-30 | 2018-11-07 | $4000 | -$0.80 | -$0.90 | 11.11% |
| 2018-06-30 | 2018-09-12 | $50000 | -$0.80 | -$0.70 | -14.29% |
| 2018-03-31 | 2018-05-09 | $-50000 | -$0.10 | -$0.85 | 88.24% |
| 2017-12-31 | 2018-02-06 | $93000 | -$0.80 | -$0.80 | 0% |
| 2017-09-30 | 2017-11-07 | $N/A | -$0.80 | -$0.83 | 4% |
| 2017-06-30 | 2017-09-07 | $2.75 million | -$0.70 | -$0.90 | 22.22% |
| 2017-03-31 | 2017-05-08 | $-5409000 | -$0.90 | -$0.80 | -12.5% |
| 2016-12-31 | 2017-02-08 | $2.56 million | -$0.80 | -$0.75 | -6.67% |
| 2016-09-30 | 2016-11-07 | $95000 | -$0.80 | -$0.80 | 0% |
| 2016-06-30 | 2016-09-07 | $2.85 million | -$0.80 | -$0.87 | 7.7% |
| 2016-03-31 | 2016-05-09 | $-2752000 | -$0.90 | -$0.93 | 3.57% |
| 2015-12-31 | 2016-02-08 | $2.75 million | -$0.50 | -$0.85 | 41.18% |
| 2015-09-30 | 2015-11-05 | $95000 | -$0.07 | -$0.09 | 22.22% |
| 2015-06-30 | 2015-09-09 | $94000 | -$0.07 | -$0.10 | 30% |
| 2015-03-31 | 2015-05-06 | $95000 | -$0.10 | -$0.12 | 16.67% |
| 2014-12-31 | 2015-02-05 | $95000 | -$0.09 | -$0.09 | 0% |
| 2014-09-30 | 2014-11-06 | $95000 | -$0.09 | -$0.11 | 18.18% |
| 2014-06-30 | 2014-09-11 | $94000 | -$0.09 | -$0.15 | 40% |
| 2014-03-31 | 2014-05-08 | $95000 | -$1.40 | -$1.40 | 0% |
| 2013-12-31 | 2014-02-05 | $95000 | -$1.10 | -$1.25 | 12% |
| 2013-09-30 | 2013-11-05 | $95000 | -$0.80 | -$1.16 | 31.03% |
| 2013-06-30 | 2013-09-11 | $289805 | -$1.20 | -$0.97 | -23.71% |
| 2013-03-31 | 2013-05-08 | $194000 | -$1.00 | -$0.92 | -8.7% |
| 2012-12-31 | 2013-01-31 | $195 | -$0.80 | -$0.90 | 11.11% |
| 2012-09-30 | 2012-11-06 | $195000 | -$0.80 | -$0.85 | 5.88% |
| 2012-06-30 | 2012-09-11 | $101000 | -$0.90 | -$0.80 | -12.5% |
| 2012-03-31 | 2012-05-08 | $230000 | -$0.90 | -$0.80 | -12.5% |
| 2011-12-31 | 2012-02-09 | $231000 | -$0.50 | -$0.60 | 16.67% |
| 2011-09-30 | 2011-11-09 | $154000 | -$1.10 | -$0.60 | -83.33% |
| 2011-06-30 | 2011-09-12 | $N/A | -$0.90 | -$0.63 | -42.86% |
| 2011-03-31 | 2011-05-11 | $N/A | -$0.70 | -$0.60 | -16.67% |
| 2010-12-31 | 2011-02-09 | $N/A | -$1.10 | -$0.80 | -37.5% |
| 2010-09-30 | 2010-11-08 | $N/A | -$0.80 | -$1.10 | 27.27% |
| 2010-06-30 | 2010-09-21 | $N/A | -$1.00 | -$0.80 | -25% |
| 2010-03-31 | 2010-05-11 | $N/A | -$1.30 | -$0.70 | -85.71% |
| 2009-12-31 | 2010-02-11 | $N/A | -$1.00 | -$1.50 | 33.33% |
| 2009-09-30 | 2009-12-02 | $N/A | -$1.11 | ||
| 2009-06-30 | 2009-06-30 | $N/A | -$1.10 | ||
| 2009-03-31 | 2009-03-31 | $N/A | -$1.67 | ||
| 2008-12-31 | 2008-12-31 | $N/A | -$0.86 | ||
| 2008-09-30 | 2008-09-30 | $N/A | -$2.91 | ||
| 2008-06-30 | 2008-06-30 | $N/A | -$4.50 | ||
| 2008-03-31 | 2008-03-31 | $N/A | -$3.91 | ||
| 2007-12-31 | 2007-12-31 | $N/A | -$3.99 | ||
| 2007-09-30 | 2007-09-30 | $N/A | -$3.93 | ||
| 2007-03-31 | 2007-03-31 | $N/A | -$29.29 | ||
| 2006-12-31 | 2006-12-31 | $N/A | -$5.81 | ||
| 2006-09-30 | 2006-09-30 | $N/A | -$8.21 | ||
| 2006-06-30 | 2006-06-30 | $N/A | -$29.85 | ||
| 2006-03-31 | 2006-03-31 | $N/A | -$19.72 | ||
| 2005-12-31 | 2005-12-31 | $N/A | -$15.27 | ||
| 2005-09-30 | 2005-09-30 | $N/A | -$11.79 | ||
| 2005-06-30 | 2005-06-30 | $20.00 | |||
| 2005-03-31 | 2005-03-31 | -$63.76 | |||
| 2004-12-31 | 2004-12-31 | -$28.75 | |||
| 2004-09-30 | 2004-09-30 | -$22.87 |
Pluristem Therapeutics Inc (PSTI) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Pluristem Therapeutics Inc (PSTI) Chart:
Pluristem Therapeutics Inc (PSTI) News:
Below you will find a list of latest news for Pluristem Therapeutics Inc (PSTI) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Pluristem Therapeutics Inc (PSTI) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest PSTI Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 3:23 PM EST | 10 | $1.22 |
| Jun 13, 2022 3:45 PM EST | 50 | $1.22 |
Pluristem Therapeutics Inc (PSTI) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000121390020016446/0001213900-20-016446-index.htm |
| 2017-06-28 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1158780/000000000017022677/0000000000-17-022677-index.htm |
| 2020-05-14 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1158780/000000000020004297/0000000000-20-004297-index.htm |
| 2020-05-21 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1158780/000000000020004542/0000000000-20-004542-index.htm |
| 2020-07-22 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1158780/000000000020006654/0000000000-20-006654-index.htm |
| 2017-05-08 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1158780/000117891317001319/0001178913-17-001319-index.htm |
| 2017-05-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000117891317001624/0001178913-17-001624-index.htm |
| 2017-06-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000117891317001864/0001178913-17-001864-index.htm |
| 2017-06-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000117891317001885/0001178913-17-001885-index.htm |
| 2017-06-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891317001887/0001178913-17-001887-index.htm |
| 2017-06-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891317001890/0001178913-17-001890-index.htm |
| 2017-06-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891317001893/0001178913-17-001893-index.htm |
| 2017-06-23 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1158780/000117891317001895/0001178913-17-001895-index.htm |
| 2017-06-28 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1158780/000117891317001956/0001178913-17-001956-index.htm |
| 2017-07-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000117891317002009/0001178913-17-002009-index.htm |
| 2017-07-07 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1158780/000117891317002011/0001178913-17-002011-index.htm |
| 2017-08-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000117891317002494/0001178913-17-002494-index.htm |
| 2017-09-07 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1158780/000117891317002643/0001178913-17-002643-index.htm |
| 2017-09-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000117891317002687/0001178913-17-002687-index.htm |
| 2017-10-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000117891317002841/0001178913-17-002841-index.htm |
| 2017-10-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000117891317002902/0001178913-17-002902-index.htm |
| 2017-10-30 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1158780/000117891317002904/0001178913-17-002904-index.htm |
| 2017-10-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000117891317002923/0001178913-17-002923-index.htm |
| 2017-10-31 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1158780/000117891317002925/0001178913-17-002925-index.htm |
| 2017-11-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1158780/000117891317003061/0001178913-17-003061-index.htm |
| 2017-12-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891317003389/0001178913-17-003389-index.htm |
| 2017-12-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891317003391/0001178913-17-003391-index.htm |
| 2017-12-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891317003393/0001178913-17-003393-index.htm |
| 2017-12-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891317003395/0001178913-17-003395-index.htm |
| 2017-12-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891317003397/0001178913-17-003397-index.htm |
| 2017-12-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891317003399/0001178913-17-003399-index.htm |
| 2017-12-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891317003401/0001178913-17-003401-index.htm |
| 2017-12-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891317003403/0001178913-17-003403-index.htm |
| 2018-01-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000117891318000091/0001178913-18-000091-index.htm |
| 2018-02-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1158780/000117891318000390/0001178913-18-000390-index.htm |
| 2018-02-06 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1158780/000117891318000392/0001178913-18-000392-index.htm |
| 2018-03-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891318000854/0001178913-18-000854-index.htm |
| 2018-03-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891318000898/0001178913-18-000898-index.htm |
| 2018-04-03 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1158780/000117891318001096/0001178913-18-001096-index.htm |
| 2018-04-03 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1158780/000117891318001098/0001178913-18-001098-index.htm |
| 2018-05-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1158780/000117891318001552/0001178913-18-001552-index.htm |
| 2018-05-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000117891318001821/0001178913-18-001821-index.htm |
| 2018-06-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000117891318001893/0001178913-18-001893-index.htm |
| 2018-09-12 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1158780/000117891318002512/0001178913-18-002512-index.htm |
| 2018-11-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1158780/000117891318002846/0001178913-18-002846-index.htm |
| 2018-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003183/0001178913-18-003183-index.htm |
| 2018-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003185/0001178913-18-003185-index.htm |
| 2018-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003187/0001178913-18-003187-index.htm |
| 2018-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003189/0001178913-18-003189-index.htm |
| 2018-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003191/0001178913-18-003191-index.htm |
| 2018-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003193/0001178913-18-003193-index.htm |
| 2018-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003195/0001178913-18-003195-index.htm |
| 2018-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003197/0001178913-18-003197-index.htm |
| 2018-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003199/0001178913-18-003199-index.htm |
| 2018-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003201/0001178913-18-003201-index.htm |
| 2019-02-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1158780/000117891319000311/0001178913-19-000311-index.htm |
| 2019-02-06 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1158780/000117891319000313/0001178913-19-000313-index.htm |
| 2019-02-06 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1158780/000117891319000315/0001178913-19-000315-index.htm |
| 2019-03-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000117891319000855/0001178913-19-000855-index.htm |
| 2019-03-18 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891319000856/0001178913-19-000856-index.htm |
| 2019-03-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891319000983/0001178913-19-000983-index.htm |
| 2019-04-03 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1158780/000117891319001034/0001178913-19-001034-index.htm |
| 2019-04-05 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1158780/000117891319001047/0001178913-19-001047-index.htm |
| 2019-04-05 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1158780/000117891319001049/0001178913-19-001049-index.htm |
| 2019-04-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000117891319001051/0001178913-19-001051-index.htm |
| 2019-04-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891319001078/0001178913-19-001078-index.htm |
| 2019-04-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891319001080/0001178913-19-001080-index.htm |
| 2019-04-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891319001082/0001178913-19-001082-index.htm |
| 2019-04-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891319001084/0001178913-19-001084-index.htm |
| 2019-04-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891319001086/0001178913-19-001086-index.htm |
| 2019-04-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000117891319001088/0001178913-19-001088-index.htm |
| 2019-04-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000117891319001141/0001178913-19-001141-index.htm |
| 2019-04-15 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1158780/000117891319001144/0001178913-19-001144-index.htm |
| 2019-04-25 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1158780/000117891319001212/0001178913-19-001212-index.htm |
| 2019-04-26 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1158780/000117891319001214/0001178913-19-001214-index.htm |
| 2019-05-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1158780/000117891319001357/0001178913-19-001357-index.htm |
| 2019-06-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000117891319001704/0001178913-19-001704-index.htm |
| 2019-06-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000117891319001751/0001178913-19-001751-index.htm |
| 2019-07-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000121390019011923/0001213900-19-011923-index.htm |
| 2019-07-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000121390019013606/0001213900-19-013606-index.htm |
| 2019-08-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000121390019015238/0001213900-19-015238-index.htm |
| 2019-09-12 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1158780/000121390019017859/0001213900-19-017859-index.htm |
| 2019-11-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1158780/000121390019022345/0001213900-19-022345-index.htm |
| 2020-02-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1158780/000121390020002786/0001213900-20-002786-index.htm |
| 2020-03-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000121390020005231/0001213900-20-005231-index.htm |
| 2020-03-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000121390020006072/0001213900-20-006072-index.htm |
| 2020-03-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000121390020007499/0001213900-20-007499-index.htm |
| 2020-03-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000121390020007923/0001213900-20-007923-index.htm |
| 2020-04-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000121390020008735/0001213900-20-008735-index.htm |
| 2020-04-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000121390020009033/0001213900-20-009033-index.htm |
| 2020-04-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000121390020010010/0001213900-20-010010-index.htm |
| 2020-04-29 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1158780/000121390020010354/0001213900-20-010354-index.htm |
| 2020-04-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000121390020010560/0001213900-20-010560-index.htm |
| 2020-04-30 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1158780/000121390020010621/0001213900-20-010621-index.htm |
| 2020-05-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000121390020011021/0001213900-20-011021-index.htm |
| 2020-05-06 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1158780/000121390020011114/0001213900-20-011114-index.htm |
| 2020-05-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000121390020011347/0001213900-20-011347-index.htm |
| 2020-05-11 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1158780/000121390020011667/0001213900-20-011667-index.htm |
| 2020-05-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000121390020012115/0001213900-20-012115-index.htm |
| 2020-05-18 | PRER14A | Preliminary Proxy Soliciting materials | https://www.sec.gov/Archives/edgar/data/1158780/000121390020012803/0001213900-20-012803-index.htm |
| 2020-05-18 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1158780/000121390020012804/0001213900-20-012804-index.htm |
| 2020-05-20 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1158780/000121390020013138/0001213900-20-013138-index.htm |
| 2020-05-20 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1158780/000121390020013139/0001213900-20-013139-index.htm |
| 2020-06-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000121390020014660/0001213900-20-014660-index.htm |
| 2020-06-30 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1158780/000121390020016199/0001213900-20-016199-index.htm |
| 2020-06-29 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000121390020016200/0001213900-20-016200-index.htm |
| 2020-06-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000121390020016201/0001213900-20-016201-index.htm |
| 2020-07-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000121390020016446/0001213900-20-016446-index.htm |
| 2020-07-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000121390020016863/0001213900-20-016863-index.htm |
| 2020-07-16 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020017673/0001213900-20-017673-index.htm |
| 2020-07-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000121390020017683/0001213900-20-017683-index.htm |
| 2020-07-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000121390020018046/0001213900-20-018046-index.htm |
| 2020-07-22 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1158780/000121390020018249/0001213900-20-018249-index.htm |
| 2020-07-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000121390020018873/0001213900-20-018873-index.htm |
| 2020-07-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000121390020019045/0001213900-20-019045-index.htm |
| 2020-07-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000121390020019289/0001213900-20-019289-index.htm |
| 2020-08-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000121390020019964/0001213900-20-019964-index.htm |
| 2020-08-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000121390020021021/0001213900-20-021021-index.htm |
| 2020-08-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000121390020023944/0001213900-20-023944-index.htm |
| 2020-09-09 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1158780/000121390020025854/0001213900-20-025854-index.htm |
| 2020-09-09 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1158780/000121390020025859/0001213900-20-025859-index.htm |
| 2020-09-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000121390020026069/0001213900-20-026069-index.htm |
| 2020-09-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000121390020026071/0001213900-20-026071-index.htm |
| 2020-09-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000121390020026074/0001213900-20-026074-index.htm |
| 2020-09-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000121390020026084/0001213900-20-026084-index.htm |
| 2020-09-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000121390020026089/0001213900-20-026089-index.htm |
| 2020-09-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000121390020026095/0001213900-20-026095-index.htm |
| 2020-09-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000121390020026101/0001213900-20-026101-index.htm |
| 2020-09-10 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1158780/000121390020026105/0001213900-20-026105-index.htm |
| 2020-09-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000121390020026715/0001213900-20-026715-index.htm |
| 2020-09-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000121390020028246/0001213900-20-028246-index.htm |
| 2020-09-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000121390020028448/0001213900-20-028448-index.htm |
| 2020-09-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000121390020028837/0001213900-20-028837-index.htm |
| 2020-10-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000121390020029553/0001213900-20-029553-index.htm |
| 2020-10-05 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1158780/000121390020030120/0001213900-20-030120-index.htm |
| 2020-10-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1158780/000121390020030411/0001213900-20-030411-index.htm |
| 2020-10-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000121390020033972/0001213900-20-033972-index.htm |
| 2020-11-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1158780/000121390020034829/0001213900-20-034829-index.htm |
| 2020-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1158780/000121390020035275/0001213900-20-035275-index.htm |
| 2017-06-30 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1158780/999999999517001718/9999999995-17-001718-index.htm |
| 2020-07-23 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1158780/999999999520001908/9999999995-20-001908-index.htm |
Pluristem Therapeutics Inc (PSTI) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Pluristem Therapeutics Inc (PSTI). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 1994%Institutional Ownership: 1164%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-10 | Chen Franco-Yehuda | Chief Financial Officer | Buy | 100,000.00 | 117,716.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020026074/0001213900-20-026074-index.htm | ||
| 2019-03-28 | Chen Franco-Yehuda | Chief Financial Officer | Buy | 60,000.00 | 137,158.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891319000983/0001178913-19-000983-index.htm | ||
| 2020-09-10 | YAKY YANAY | CEO & President | Buy | 500,000.00 | 1,425,304.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020026071/0001213900-20-026071-index.htm | ||
| 2020-09-10 | Zami Aberman | Executive Chairman | Buy | 500,000.00 | 1,493,973.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020026069/0001213900-20-026069-index.htm | ||
| 2019-03-28 | Chen Franco-Yehuda | Chief Financial Officer | Buy | 40,000.00 | 177,158.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891319000983/0001178913-19-000983-index.htm | ||
| 2020-05-27 | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER | 10% Share Holder | Buy | 90,000.00 | 8.14 | 732,600.00 | 2,601,311.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020016201/0001213900-20-016201-index.htm |
| 2018-12-19 | ISRAEL BEN-YORAM | Director | Buy | 49,875.00 | 265,931.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003189/0001178913-18-003189-index.htm | ||
| 2020-05-28 | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER | 10% Share Holder | Buy | 75,898.00 | 8.16 | 619,327.68 | 2,677,209.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020016201/0001213900-20-016201-index.htm |
| 2020-05-31 | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER | 10% Share Holder | Buy | 1,797.00 | 7.95 | 14,286.15 | 2,679,006.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020016201/0001213900-20-016201-index.htm |
| 2020-06-01 | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER | 10% Share Holder | Buy | 22,796.00 | 7.85 | 178,948.60 | 2,701,802.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020016201/0001213900-20-016201-index.htm |
| 2017-12-14 | Moria Kwiat | Director | Buy | 90,000.00 | 277,500.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891317003389/0001178913-17-003389-index.htm | ||
| 2017-06-21 | Erez Egozi | Chief Financial Officer | Buy | 150,000.00 | 278,000.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891317001893/0001178913-17-001893-index.htm | ||
| 2020-06-02 | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER | 10% Share Holder | Buy | 117,489.00 | 7.57 | 889,391.73 | 2,819,291.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020016201/0001213900-20-016201-index.htm |
| 2020-06-04 | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER | 10% Share Holder | Buy | 7,610.00 | 7.86 | 59,814.60 | 2,826,901.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020016201/0001213900-20-016201-index.htm |
| 2020-06-05 | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER | 10% Share Holder | Buy | 60,000.00 | 7.82 | 469,200.00 | 2,886,901.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020016201/0001213900-20-016201-index.htm |
| 2020-06-08 | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER | 10% Share Holder | Buy | 178,717.00 | 7.36 | 1,315,357.12 | 3,065,618.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020016201/0001213900-20-016201-index.htm |
| 2018-12-19 | Moria Kwiat | Director | Buy | 33,750.00 | 311,250.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003195/0001178913-18-003195-index.htm | ||
| 2020-06-09 | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER | 10% Share Holder | Buy | 72,142.00 | 7.15 | 515,815.30 | 3,137,760.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020016201/0001213900-20-016201-index.htm |
| 2018-12-19 | ISRAEL BEN-YORAM | Director | Buy | 49,875.00 | 315,806.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003189/0001178913-18-003189-index.htm | ||
| 2020-06-10 | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER | 10% Share Holder | Buy | 25,000.00 | 6.91 | 172,750.00 | 3,162,760.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020016201/0001213900-20-016201-index.htm |
| 2020-06-18 | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER | 10% Share Holder | Buy | 49,000.00 | 7.36 | 360,640.00 | 3,211,760.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020016201/0001213900-20-016201-index.htm |
| 2018-12-19 | Moria Kwiat | Director | Buy | 33,750.00 | 345,000.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003195/0001178913-18-003195-index.htm | ||
| 2020-07-27 | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER | 10% Share Holder | Buy | 49,396.00 | 8.34 | 411,962.64 | 3,460,842.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020018873/0001213900-20-018873-index.htm |
| 2020-07-28 | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER | 10% Share Holder | Buy | 81,198.00 | 8.46 | 686,935.08 | 3,542,040.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020019045/0001213900-20-019045-index.htm |
| 2017-06-21 | YAKY YANAY | Co-CEO & President | Buy | 2,000,000.00 | 3,651,616.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891317001890/0001178913-17-001890-index.htm | ||
| 2020-07-29 | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER | 10% Share Holder | Buy | 121,926.00 | 9.03 | 1,100,991.78 | 3,663,966.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020019289/0001213900-20-019289-index.htm |
| 2020-07-30 | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER | 10% Share Holder | Buy | 51,235.00 | 9.19 | 470,849.65 | 3,715,201.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020019964/0001213900-20-019964-index.htm |
| 2020-07-31 | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER | 10% Share Holder | Buy | 14,536.00 | 9.43 | 137,074.48 | 3,729,737.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020019964/0001213900-20-019964-index.htm |
| 2019-04-08 | Moria Kwiat | Director | Buy | 28,571.00 | 0.70 | 19,999.70 | 373,571.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891319001080/0001178913-19-001080-index.htm |
| 2020-09-23 | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER | 10% Share Holder | Buy | 8,458.00 | 9.05 | 76,544.90 | 3,738,195.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020028246/0001213900-20-028246-index.htm |
| 2020-09-23 | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER | 10% Share Holder | Buy | 2,276.00 | 8.98 | 20,438.48 | 3,740,471.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020028246/0001213900-20-028246-index.htm |
| 2020-09-24 | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER | 10% Share Holder | Buy | 34,800.00 | 9.02 | 313,896.00 | 3,775,271.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020028448/0001213900-20-028448-index.htm |
| 2020-09-28 | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER | 10% Share Holder | Buy | 13,189.00 | 9.49 | 125,163.61 | 3,788,460.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020028837/0001213900-20-028837-index.htm |
| 2020-09-29 | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER | 10% Share Holder | Buy | 60,123.00 | 9.76 | 586,800.48 | 3,848,583.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020029553/0001213900-20-029553-index.htm |
| 2019-04-08 | ISRAEL BEN-YORAM | Director | Buy | 71,429.00 | 0.70 | 50,000.30 | 387,235.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891319001082/0001178913-19-001082-index.htm |
| 2017-12-14 | Erez Egozi | Chief Financial Officer | Buy | 110,000.00 | 388,000.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891317003393/0001178913-17-003393-index.htm | ||
| 2018-12-19 | YAKY YANAY | Co-CEO & President | Buy | 280,000.00 | 3,931,616.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003199/0001178913-18-003199-index.htm | ||
| 2020-09-30 | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER | 10% Share Holder | Buy | 139,006.00 | 10.34 | 1,437,322.04 | 3,987,589.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020029553/0001213900-20-029553-index.htm |
| 2018-12-19 | DORON SHORRER | Director | Buy | 63,375.00 | 400,583.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003183/0001178913-18-003183-index.htm | ||
| 2020-10-29 | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER | 10% Share Holder | Buy | 20,000.00 | 9.20 | 184,000.00 | 4,007,589.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020033972/0001213900-20-033972-index.htm |
| 2020-10-30 | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER | 10% Share Holder | Buy | 25,000.00 | 9.60 | 240,000.00 | 4,032,589.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020034829/0001213900-20-034829-index.htm |
| 2020-10-30 | WOLF CAPITAL - LIMITED PARTNERSHIP CLOVER | 10% Share Holder | Buy | 25,000.00 | 9.42 | 235,500.00 | 4,057,589.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020034829/0001213900-20-034829-index.htm |
| 2017-12-14 | ISRAEL BEN-YORAM | Director | Buy | 133,000.00 | 411,250.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891317003399/0001178913-17-003399-index.htm | ||
| 2018-12-19 | YAKY YANAY | Co-CEO & President | Buy | 250,000.00 | 4,181,616.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003199/0001178913-18-003199-index.htm | ||
| 2019-04-08 | YAKY YANAY | Co-CEO & President | Buy | 71,429.00 | 0.70 | 50,000.30 | 4,253,045.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891319001084/0001178913-19-001084-index.htm |
| 2017-06-21 | Zami Aberman | Co-CEO & Chairman | Buy | 2,000,000.00 | 4,318,298.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891317001887/0001178913-17-001887-index.htm | ||
| 2018-12-19 | DORON SHORRER | Director | Buy | 49,875.00 | 450,458.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003183/0001178913-18-003183-index.htm | ||
| 2018-12-19 | Zami Aberman | Co-CEO & Chairman | Buy | 300,000.00 | 4,618,298.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003201/0001178913-18-003201-index.htm | ||
| 2019-04-08 | DORON SHORRER | Director | Buy | 14,286.00 | 0.70 | 10,000.20 | 464,744.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891319001088/0001178913-19-001088-index.htm |
| 2018-12-19 | Erez Egozi | Chief Financial Officer | Buy | 80,000.00 | 468,000.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003185/0001178913-18-003185-index.htm | ||
| 2018-12-19 | Zami Aberman | Co-CEO & Chairman | Buy | 250,000.00 | 4,868,298.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003201/0001178913-18-003201-index.htm | ||
| 2019-04-08 | Zami Aberman | Co-CEO & Chairman | Buy | 71,429.00 | 0.70 | 50,000.30 | 4,939,727.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891319001086/0001178913-19-001086-index.htm |
| 2017-12-14 | HAVA MERETZKI | Director | Buy | 90,000.00 | 505,208.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891317003401/0001178913-17-003401-index.htm | ||
| 2017-12-14 | ISAAC BRAUN | Director | Buy | 90,000.00 | 505,208.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891317003403/0001178913-17-003403-index.htm | ||
| 2018-03-16 | MARK GERMAIN | Director | Sell | 11,640.00 | 1.48 | 17,227.20 | 513,944.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891318000898/0001178913-18-000898-index.htm |
| 2018-12-19 | Erez Egozi | Chief Financial Officer | Buy | 50,000.00 | 518,000.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003185/0001178913-18-003185-index.htm | ||
| 2017-12-14 | NACHUM ROSMAN | Director | Buy | 133,000.00 | 520,464.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891317003391/0001178913-17-003391-index.htm | ||
| 2018-03-15 | MARK GERMAIN | Director | Sell | 34,233.00 | 1.48 | 50,664.84 | 525,584.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891318000898/0001178913-18-000898-index.htm |
| 2018-12-19 | Erez Egozi | Chief Financial Officer | Buy | 30,000.00 | 548,000.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003185/0001178913-18-003185-index.htm | ||
| 2018-12-19 | HAVA MERETZKI | Director | Buy | 47,250.00 | 552,458.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003187/0001178913-18-003187-index.htm | ||
| 2018-12-19 | ISAAC BRAUN | Director | Buy | 47,250.00 | 552,458.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003191/0001178913-18-003191-index.htm | ||
| 2018-03-14 | MARK GERMAIN | Director | Sell | 23,818.00 | 1.50 | 35,727.00 | 559,817.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891318000854/0001178913-18-000854-index.htm |
| 2020-09-10 | Moria Kwiat | Director | Buy | 20,000.00 | 57,357.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020026101/0001213900-20-026101-index.htm | ||
| 2018-12-19 | MARK GERMAIN | Director | Buy | 62,625.00 | 576,569.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003193/0001178913-18-003193-index.htm | ||
| 2017-12-14 | MARK GERMAIN | Director | Buy | 131,000.00 | 583,635.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891317003395/0001178913-17-003395-index.htm | ||
| 2018-12-19 | NACHUM ROSMAN | Director | Buy | 63,375.00 | 583,839.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003197/0001178913-18-003197-index.htm | ||
| 2018-12-19 | HAVA MERETZKI | Director | Buy | 33,750.00 | 586,208.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003187/0001178913-18-003187-index.htm | ||
| 2018-12-19 | ISAAC BRAUN | Director | Buy | 33,750.00 | 586,208.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003191/0001178913-18-003191-index.htm | ||
| 2018-12-19 | MARK GERMAIN | Director | Buy | 49,125.00 | 625,694.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003193/0001178913-18-003193-index.htm | ||
| 2018-12-19 | NACHUM ROSMAN | Director | Buy | 49,875.00 | 633,714.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891318003197/0001178913-18-003197-index.htm | ||
| 2019-04-08 | ISAAC BRAUN | Director | Buy | 50,000.00 | 0.70 | 35,000.00 | 636,208.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891319001078/0001178913-19-001078-index.htm |
| 2020-09-10 | DORON SHORRER | Director | Buy | 20,000.00 | 66,474.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020026089/0001213900-20-026089-index.htm | ||
| 2017-12-14 | DORON SHORRER | Director | Buy | 133,000.00 | 769,708.00 | https://www.sec.gov/Archives/edgar/data/1158780/000117891317003397/0001178913-17-003397-index.htm | ||
| 2020-09-10 | MARK GERMAIN | Director | Buy | 20,000.00 | 82,569.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020026095/0001213900-20-026095-index.htm | ||
| 2020-09-10 | ISAAC BRAUN | Director | Buy | 20,000.00 | 83,621.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020026084/0001213900-20-026084-index.htm | ||
| 2020-09-10 | YAKY YANAY | CEO & President | Buy | 500,000.00 | 925,304.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020026071/0001213900-20-026071-index.htm | ||
| 2020-09-10 | Zami Aberman | Executive Chairman | Buy | 500,000.00 | 993,973.00 | https://www.sec.gov/Archives/edgar/data/1158780/000121390020026069/0001213900-20-026069-index.htm |